Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.36 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715395 | 0.94 | ESR1 (0.48) | ESR1ESR2HPGDHDAC6ABHD6 | |
| SCHEMBL722449 | 0.82 | ESR1 (0.48) | ESR1ESR2HPGDCYP11B2 | |
| SCHEMBL720039 | 0.80 | HPGD (0.41) | ESR1ESR2HPGDECE2HTT | |
| Trifluoroacetic Acid SCHEMBL722015 | 0.79 | HRH4 (0.40) | ESR1ESR2HPGDHDAC6HDAC1 | |
| SCHEMBL719456 | 0.78 | ESR1 (0.56) | ESR1ESR2HDAC6ABHD6CA12 | |
| SCHEMBL718874 | 0.77 | ESR1 (0.43) | ESR1ESR2CYP11B2 | |
| SCHEMBL722817 | 0.76 | ESR1 (0.51) | ESR1ESR2HPGDHDAC6ABHD6 | |
| Water SCHEMBL3709828 | 0.75 | ESR1 (0.54) | ESR1ESR2HDAC6ABHD6CA12 | |
| Water SCHEMBL3709830 | 0.75 | ESR1 (0.57) | ESR1ESR2HDAC6ABHD6CA12 | |
| SCHEMBL31164739 | 0.75 | ESR1 (0.53) | ESR1ESR2HDAC6ABHD6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA2, CHRNA5, CHRNA10 | ESR1 1178/4885ESR2 825/4885HPGD 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.